Insider activity at Day One Biopharmaceuticals, Inc. has been all selling for a year now: about $672,000 from five sellers, and zero buyers with their own money.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Merendino Lauren | Executive Officer | Sell | 5,814 | $11.60 | $67K | SEC |
| Feb 18, 2026 | Dubow Adam | Officer | Sell | 6,395 | $11.60 | $74K | SEC |
| Feb 18, 2026 | York Charles N II | CFO | Sell | 6,065 | $11.60 | $70K | SEC |
| Feb 18, 2026 | Bender Jeremy | CEO | Sell | 15,459 | $11.60 | $179K | SEC |
| Feb 18, 2026 | VASCONCELLES MICHAEL | Officer | Sell | 2,728 | $11.60 | $32K | SEC |
| Nov 18, 2025 | Dubow Adam | Officer | Sell | 4,319 | $8.91 | $38K | SEC |
| Nov 18, 2025 | York Charles N II | CFO | Sell | 4,062 | $8.91 | $36K | SEC |
| Nov 18, 2025 | Merendino Lauren | Executive Officer | Sell | 3,726 | $8.91 | $33K | SEC |
| Nov 18, 2025 | Bender Jeremy | CEO | Sell | 15,894 | $8.91 | $142K | SEC |
| Aug 19, 2025 | York Charles N II | CFO | Sell | 4,106 | $6.77 | $28K | SEC |
| Aug 19, 2025 | Dubow Adam | Officer | Sell | 4,365 | $6.77 | $30K | SEC |
| Aug 19, 2025 | Bender Jeremy | CEO | Sell | 16,058 | $6.77 | $109K | SEC |
| Aug 19, 2025 | Merendino Lauren | Executive Officer | Sell | 3,766 | $6.77 | $25K | SEC |
| May 19, 2025 | York Charles N II | CFO | Sell | 4,282 | $6.26 | $27K | SEC |
| May 19, 2025 | Bender Jeremy | CEO | Sell | 13,964 | $6.26 | $87K | SEC |
In the last 12 months Day One Biopharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $672,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in DAWN was filed on 2026-02-18.
No congressional trades in DAWN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).